BRIEF-Dupixent Approved In US As First New Targeted Therapy In Over Decade For Chronic Spontaneous Urticaria

Reuters
19 Apr
BRIEF-Dupixent Approved In US As First New Targeted Therapy In Over Decade For Chronic Spontaneous Urticaria

April 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:

  • DUPIXENT® (DUPILUMAB) APPROVED IN THE U.S. AS THE FIRST NEW TARGETED THERAPY IN OVER A DECADE FOR CHRONIC SPONTANEOUS URTICARIA (CSU)

Source text: ID:nGNX23rJSX

Further company coverage: REGN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10